Go Pro
→ Bezos… DOOMED (From Paradigm Press) (Ad)tc pixel Free RVX Stock Alerts

Resverlogix (RVX) Competitors

Resverlogix logo
C$0.10 +0.01 (+5.26%)
As of 09/3/2026 03:49 PM Eastern
Compare

RVX vs. SCYB, COM, NVH, PDP, and COV

Should you buy Resverlogix stock or one of its competitors? Resverlogix's main competitors and comparable companies include Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Novoheart (NVH), Pediapharm (PDP), and Covalon Technologies (COV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Resverlogix compare to Scythian Biosciences?

Scythian Biosciences (CVE:SCYB) and Resverlogix (TSE:RVX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

In the previous week, Scythian Biosciences' average media sentiment score of 0.00 equaled Resverlogix'saverage media sentiment score.

Company Overall Sentiment
Scythian Biosciences Neutral
Resverlogix Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scythian BiosciencesN/AN/AN/AN/AN/A
ResverlogixN/AN/A-C$2.81M-C$0.04N/A

0.0% of Resverlogix shares are owned by institutional investors. 42.7% of Resverlogix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Resverlogix's return on equity of 10.92% beat Scythian Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Scythian BiosciencesN/A N/A N/A
Resverlogix N/A 10.92%-34.90%

Summary

Resverlogix beats Scythian Biosciences on 3 of the 4 factors compared between the two stocks.

How does Resverlogix compare to 138267 (COM.TO)?

138267 (COM.TO) (TSE:COM) and Resverlogix (TSE:RVX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

Resverlogix's return on equity of 10.92% beat 138267 (COM.TO)'s return on equity.

Company Net Margins Return on Equity Return on Assets
138267 (COM.TO)N/A N/A N/A
Resverlogix N/A 10.92%-34.90%

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
138267 (COM.TO)N/AN/AN/AN/AN/A
ResverlogixN/AN/A-C$2.81M-C$0.04N/A

0.0% of Resverlogix shares are held by institutional investors. 42.7% of Resverlogix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, 138267 (COM.TO)'s average media sentiment score of 0.00 equaled Resverlogix'saverage media sentiment score.

Company Overall Sentiment
138267 (COM.TO) Neutral
Resverlogix Neutral

Summary

Resverlogix beats 138267 (COM.TO) on 3 of the 4 factors compared between the two stocks.

How does Resverlogix compare to Novoheart?

Resverlogix (TSE:RVX) and Novoheart (CVE:NVH) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

0.0% of Resverlogix shares are owned by institutional investors. 42.7% of Resverlogix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Resverlogix has higher earnings, but lower revenue than Novoheart. Novoheart is trading at a lower price-to-earnings ratio than Resverlogix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ResverlogixN/AN/A-C$2.81M-C$0.04N/A
NovoheartC$423.50K236.08-C$7.17M-C$0.04N/A

In the previous week, Resverlogix's average media sentiment score of 0.00 equaled Novoheart'saverage media sentiment score.

Company Overall Sentiment
Resverlogix Neutral
Novoheart Neutral

Resverlogix's return on equity of 10.92% beat Novoheart's return on equity.

Company Net Margins Return on Equity Return on Assets
ResverlogixN/A 10.92% -34.90%
Novoheart N/A N/A N/A

Summary

Resverlogix beats Novoheart on 5 of the 8 factors compared between the two stocks.

How does Resverlogix compare to Pediapharm?

Pediapharm (CVE:PDP) and Resverlogix (TSE:RVX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

Resverlogix has lower revenue, but higher earnings than Pediapharm. Pediapharm is trading at a lower price-to-earnings ratio than Resverlogix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PediapharmC$11.16M5.95-C$16.15M-C$0.07N/A
ResverlogixN/AN/A-C$2.81M-C$0.04N/A

Resverlogix's return on equity of 10.92% beat Pediapharm's return on equity.

Company Net Margins Return on Equity Return on Assets
PediapharmN/A N/A N/A
Resverlogix N/A 10.92%-34.90%

0.0% of Resverlogix shares are held by institutional investors. 42.7% of Resverlogix shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Pediapharm's average media sentiment score of 0.00 equaled Resverlogix'saverage media sentiment score.

Company Overall Sentiment
Pediapharm Neutral
Resverlogix Neutral

Summary

Resverlogix beats Pediapharm on 6 of the 8 factors compared between the two stocks.

How does Resverlogix compare to Covalon Technologies?

Covalon Technologies (CVE:COV) and Resverlogix (TSE:RVX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk.

In the previous week, Covalon Technologies had 1 more articles in the media than Resverlogix. MarketBeat recorded 1 mentions for Covalon Technologies and 0 mentions for Resverlogix. Covalon Technologies' average media sentiment score of 0.06 beat Resverlogix's score of 0.00 indicating that Covalon Technologies is being referred to more favorably in the media.

Company Overall Sentiment
Covalon Technologies Neutral
Resverlogix Neutral

Covalon Technologies has a beta of 1.230106, suggesting that its stock price is 23% more volatile than the broader market. Comparatively, Resverlogix has a beta of 0.119614, suggesting that its stock price is 88% less volatile than the broader market.

Covalon Technologies has higher revenue and earnings than Resverlogix. Resverlogix is trading at a lower price-to-earnings ratio than Covalon Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Covalon TechnologiesC$32.68M2.58C$2.39MC$0.1619.06
ResverlogixN/AN/A-C$2.81M-C$0.04N/A

Covalon Technologies has a net margin of 12.78% compared to Resverlogix's net margin of 0.00%. Covalon Technologies' return on equity of 15.04% beat Resverlogix's return on equity.

Company Net Margins Return on Equity Return on Assets
Covalon Technologies12.78% 15.04% -3.25%
Resverlogix N/A 10.92%-34.90%

0.2% of Covalon Technologies shares are owned by institutional investors. Comparatively, 0.0% of Resverlogix shares are owned by institutional investors. 48.7% of Covalon Technologies shares are owned by insiders. Comparatively, 42.7% of Resverlogix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Covalon Technologies beats Resverlogix on 12 of the 12 factors compared between the two stocks.

Get Resverlogix News Delivered to You Automatically

Sign up to receive the latest news and ratings for RVX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RVX vs. The Competition

Export
MetricResverlogixBiotechnology IndustryHealthcare SectorTSE Exchange
Market CapC$32.71MC$4.03BC$7.26BC$12.57B
Dividend Yield7.02%3.60%2.53%6.25%
P/E Ratio-2.5012.66273.2839.47
Price / SalesN/A1,309.16613.489.82
Price / Cash132.50106.8777.8282.29
Price / Book-0.3516.2912.894.71
Net Income-C$2.81M-C$22.72MC$3.47BC$299.09M
7 Day PerformanceN/A0.34%0.61%-0.31%
1 Month PerformanceN/A8.52%5.73%3.12%
1 Year PerformanceN/A52.66%25.37%28.73%

Resverlogix Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RVX
Resverlogix
N/AC$0.10
+5.3%		N/A-2.4%C$32.71MN/AN/A19
SCYB
Scythian Biosciences
N/AC$3.49
-5.9%		N/A+0.0%C$102.38MN/AN/AN/A
COM
138267 (COM.TO)
N/AN/AN/AN/AC$102.19MN/AN/AN/A
NVH
Novoheart
N/AC$0.53
+1.9%		N/A+0.0%C$99.98MC$423.50KN/AN/A
PDP
Pediapharm
N/AC$0.30
+1.7%		N/A+0.0%C$66.36MC$11.16MN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:RVX) was last updated on 9/4/2026 by MarketBeat.com Staff.
From Our Partners
The 2026 beginners Guide to Gold IRAs
Gold trades near record highs while silver just topped $81 an ounce for the first time ever. Thousands of A...
Goldco Direct, LLC | Sponsoredtc pixel
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
Before Anthropic becomes impossible to ignore...
Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...
The Oxford Club | Sponsoredtc pixel
Are you leaving Social Security money on the table?
Most retirement plans still have gaps in them... The quiet ones that don't show up until it's too late to fix....
Money Pickle | Sponsoredtc pixel
How Long Does $2.5M Last in Retirement?
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...
SmartAsset | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
The cat is out the bag
Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...
Porter & Company | Sponsoredtc pixel